Startups
Servier US
Edit

Servier US

http://servier.us/
Last activity: 24.07.2025
Active
Categories: DevelopmentEventFutureHealthTechLearnMedtechNonprofitResearchSalesScience
Welcome to Servier Pharmaceuticals, where we are driven by science and dedicated to serving patients. Learn more about our commitment.
TwitterLinkedInEmail
Mentions
10

Overview

Location
United States, Massachusetts, Boston

Mentions in press and media 10

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Aug 6, 2024Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant GliomaVORANIGO is the first and only FDA-approved targeted treatment in Grade 2 IDH-mutant glioma VORANIGO demonstrated significant improvement in progression free survival with a favorable safety profile in a pivotal Phase 3 study of patients wi...
May 14, 2024Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation SurveyServier is ranked 1st for patient centricity, information sharing, integrity, services 'beyond the pill', engagement and communication and overall familiarity in the industry BOSTON, May 14, 2024 /PRNewswire/ -- Servier, a leader in oncolog...
Aug 25, 2021Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma
Aug 2, 2021Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia USA - English France - Français USA - English
Jun 16, 2021Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research
May 5, 2021Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Cholangiocarcinoma
Oct 12, 2020Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™
Sep 24, 2020Servier and MBC BioLabs Announce Winner of the 2020 Servier Golden Ticket
Advancing science to fight rare cancersThe biotech industry is at a crossroads. Innovation may be challenged by new policy and industry pressures, making partnerships and acquisitions more critical in the drive to drug discovery. Here, both the CEO of Servier Pharmaceuticals and...

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Servier US

What has the press written about Servier US?

Parsers VC has collected 10 articles mentioning Servier US, among them “Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma” (Aug 6, 2024) and “Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey” (May 14, 2024).

Is Servier US still active?

Yes, Servier US is active; its latest activity on Parsers VC dates from Jul 24, 2025.